← Leaderboards
Kelly E Dunn
Johns Hopkins University
$16,976,262
Attributed
$24,408,332
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,408,332 · 12
By mechanism
R01$15,410,170 · 6
UH3$3,632,165 · 1
UG3$2,918,116 · 2
UE5$1,308,776 · 1
R34$693,605 · 1
R21$445,500 · 1
Top collaborators
- Claudia Michelle Campbell8 shared
- Phillip Phan4 shared
- Andrew S Huhn3 shared
- Denis Godwin Antoine2 shared
- Laura Brandt1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Ryan G Vandrey$11,502,880
- Paul B Rosenberg$14,116,062
- Matthew Wayne Johnson$11,865,009
- Lori Latowski Grover$726,284
- Claudia Michelle Campbell$14,946,130
Others in their field
Top investigators on “Evaluation”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- David Heimbrook · Leidos Biomedical Research, Inc.$564,050,020
- Lawrence Corey · Fred Hutchinson Cancer Center$559,122,174
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$489,869,793
- Jeffrey P Krischer · University Of South Florida$466,087,841
- Judith S. Currier · University Of California Los Angeles$403,175,569
Research focus
EvaluationPharmaceutical PreparationsParticipantEnrollmentOpioidLaboratoriesPublic HealthDouble-Blind MethodPlacebosDoseResponsePersonsDesignPainOpioid WithdrawalAnalgesicsOpioid Use DisorderProviderPrimary OutcomeClinical TreatmentSeveritiesRandomizedReportingWoman
Grant awards (36)
Developing an FDA-Qualified Clinical Outcomes Assessment for Opioid Withdrawal$702,974
UG3 · FY2025 · DA
Randomized Clinical Trial Intervention to Treat Chronic Pain Among Persons Maintained on Methadone for Opioid Use Disorder$659,647
R01 · FY2025 · DA · contact PI
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype$621,790
R01 · FY2025 · DA · contact PI
Discovery to Commercialization Program for Substance Abuse Prevention and Treatment (D2C: SAPT)$321,078
UE5 · FY2025 · DA
Randomized Clinical Trial Intervention to Treat Chronic Pain Among Persons Maintained on Methadone for Opioid Use Disorder$692,181
R01 · FY2024 · DA
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype$654,779
R01 · FY2024 · DA · contact PI
Discovery to Commercialization Program for Substance Abuse Prevention and Treatment (D2C: SAPT)$321,897
UE5 · FY2024 · DA
Randomized Clinical Trial Intervention to Treat Chronic Pain Among Persons Maintained on Methadone for Opioid Use Disorder$692,181
R01 · FY2023 · DA · contact PI
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype$654,779
R01 · FY2023 · DA · contact PI
Discovery to Commercialization Program for Substance Abuse Prevention and Treatment (D2C: SAPT)$320,525
UE5 · FY2023 · DA
Randomized Clinical Trial Intervention to Treat Chronic Pain Among Persons Maintained on Methadone for Opioid Use Disorder$743,191
R01 · FY2022 · DA · contact PI
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype$654,779
R01 · FY2022 · DA · contact PI
Discovery to Commercialization Program for Substance Abuse Prevention and Treatment (D2C: SAPT)$345,276
UE5 · FY2022 · DA
Evaluating Suvorexant for Sleep Disturbance in Opioid Use Disorder$3,632,165
UH3 · FY2021 · DA
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype$668,814
R01 · FY2021 · DA · contact PI
Using Cannabinoids to Enhance Opioid Analgesic Effects in Humans$657,143
R01 · FY2021 · DA · contact PI
Evaluating Suvorexant for Sleep Disturbance in Opioid Use Disorder$1,076,067
UG3 · FY2020 · DA
Opioid and cannabinoid combinations in laboratory and clinical pain$747,430
R01 · FY2020 · DA
Evaluating Suvorexant for Sleep Disturbance in Opioid Use Disorder$1,139,075
UG3 · FY2019 · DA
Using Cannabinoids to Enhance Opioid Analgesic Effects in Humans$689,500
R01 · FY2019 · DA · contact PI
Developing a Method to Empirically-evaluate Treatment for Pain within Opioid Maintenance Patients$116,345
R34 · FY2019 · DA · contact PI
Opioid and cannabinoid combinations in laboratory and clinical pain$752,257
R01 · FY2018 · DA
Using Cannabinoids to Enhance Opioid Analgesic Effects in Humans$694,031
R01 · FY2018 · DA · contact PI
A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans$621,994
R01 · FY2018 · DA · contact PI
Bupropion-Enhanced CM for Cocaine Dependence$506,751
R01 · FY2018 · DA · contact PI
Developing a Method to Empirically-evaluate Treatment for Pain within Opioid Maintenance Patients$268,601
R34 · FY2018 · DA · contact PI
Opioid and cannabinoid combinations in laboratory and clinical pain$749,483
R01 · FY2017 · DA
Using Cannabinoids to Enhance Opioid Analgesic Effects in Humans$681,242
R01 · FY2017 · DA · contact PI
A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans$655,032
R01 · FY2017 · DA · contact PI
Developing a Method to Empirically-evaluate Treatment for Pain within Opioid Maintenance Patients$308,659
R34 · FY2017 · DA · contact PI
Using Cannabinoids to Enhance Opioid Analgesic Effects in Humans$682,169
R01 · FY2016 · DA · contact PI
A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans$648,482
R01 · FY2016 · DA · contact PI
A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans$645,205
R01 · FY2015 · DA · contact PI
A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans$637,310
R01 · FY2014 · DA · contact PI
Development and Validation of a Computerized Opioid Overdose Intervention$202,500
R21 · FY2014 · DA · contact PI
Development and Validation of a Computerized Opioid Overdose Intervention$243,000
R21 · FY2013 · DA · contact PI